Sequenom's Q1 Revenues Rise as Firm Details Plan for T21 Test

The firm posted 22 percent revenue growth, with increases in both instruments and consumables. It also laid out plans for development of its non-invasive T21 test, which it hopes to have on the market as an LDT by the end of 2011.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories